Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
107.94M | 110.32M | 0.00 | 0.00 | 0.00 | Gross Profit |
107.94M | 110.32M | -2.22M | -1.04M | -629.00K | EBIT |
-137.57M | -89.88M | -191.26M | -65.02M | -32.10M | EBITDA |
-99.06M | -64.14M | -184.74M | -63.93M | -31.47M | Net Income Common Stockholders |
-107.35M | -70.69M | -186.10M | -63.93M | -32.09M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
587.38M | 702.02M | 254.84M | 104.62M | 46.60M | Total Assets |
711.33M | 825.13M | 313.82M | 128.78M | 57.69M | Total Debt |
54.08M | 97.63M | 88.13M | 100.00K | 0.00 | Net Debt |
-51.60M | -296.96M | 23.95M | -104.52M | -46.60M | Total Liabilities |
256.54M | 339.75M | 108.86M | 250.30M | 121.41M | Stockholders Equity |
454.79M | 485.38M | 204.95M | -121.52M | -63.72M |
Cash Flow | Free Cash Flow | |||
-96.90M | 186.15M | -101.58M | -60.02M | -29.55M | Operating Cash Flow |
-83.47M | 207.57M | -99.30M | -54.24M | -28.66M | Investing Cash Flow |
-183.04M | -154.51M | -117.67M | -79.98M | -888.00K | Financing Cash Flow |
-24.09M | 279.16M | 252.63M | 118.45M | 41.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $3.64B | 7.05 | 33.08% | ― | 91.12% | ― | |
55 Neutral | $3.52B | ― | -35.56% | ― | -41.66% | -180.15% | |
54 Neutral | $3.50B | ― | -51.57% | ― | 730.42% | 31.63% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
52 Neutral | $3.97B | ― | -418.97% | ― | 48.88% | 39.30% | |
48 Neutral | $2.83B | 60.02 | 8.99% | ― | -34.02% | -65.83% | |
43 Neutral | $3.37B | ― | -386.33% | ― | 33.46% | 26.72% |
On May 14, 2025, Arcellx, Inc. announced positive results from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for patients with relapsed or refractory multiple myeloma. The study demonstrated a 97% overall response rate and a 68% complete response rate, with no delayed neurotoxicities observed. These findings will be presented at the EHA 2025 Congress, highlighting the potential of anito-cel to address unmet needs in multiple myeloma treatment. The company, in collaboration with Kite, plans to commercialize anito-cel, with a 2026 launch anticipated.
The most recent analyst rating on (ACLX) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Arcellx Inc stock, see the ACLX Stock Forecast page.
On March 18, 2025, Arcellx, Inc. announced changes to its Board of Directors, with Derek Yoon resigning and Andrew Galligan and Kristin Myers being appointed to fill vacancies. These appointments bring significant experience to the company, with Galligan’s financial leadership and Myers’ healthcare expertise expected to support Arcellx’s strategic growth and anticipated commercial launch of its lead product candidate, anito-cel, in 2026.